Login Register Cart 0
Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Efficacy Analysis of PTCD + TACE vs PTCD + Apatinib in the Treatment of HCC with Obstructive Jaundice: A Retrospective Study

In Press, (this is not the final "Version of Record"). Available online 18 July, 2024
Author(s): Haohao Lu, Bin Liang, Xiangwen Xia and Chuansheng Zheng*
Published on: 18 July, 2024

DOI: 10.2174/0118715206313132240712101607

Price: $95

Abstract

Purpose: The aim was to evaluate the safety and effectiveness of PTCD combined with TACE in the treatment of hepatocellular carcinoma with obstructive jaundice and to compare the efficacy of TACE in patients with different levels of bilirubin after PTCD.

Methods: The clinical data of 141 patients with HCC complicated with obstructive jaundice were analyzed retrospectively. The patients underwent PTCD first. When the total bilirubin decreased, the patients received TACE or Apatinib treatment. They were divided into two groups: (1) PTCD+TACE group, N=68; (2) PTCD+Apatinib group, N=73.

Results: The PTCD+TACE group had higher ORR and DCR than the PTCD+Apatinib group (57.4% vs 12.3%, p < 0.001;80.9% vs 60.3%, p = 0.010). The mPFS of the PTCD+TACE group was longer than that of the PTCD+Apatinib group (7.1 months vs 3.8 months, p < 0.001). The mOS of the PTCD+TACE group was longer than that of the PTCD+Apatinib group(11.5 months vs 7.7 months, p < 0.001). In the subgroup analysis of the PTCD+TACE group, the results showed that the survival benefits of the groups with total bilirubin <2 times and 2-3 times were greater.

Conclusion: In patients with HCC and obstructive jaundice, superselective TACE(lipiodol+epirubicin emulsion) significantly prolonged OS and PFS compared with Apatinib after using PTCD to reduce total bilirubin to <100umol/L. Patients whose total bilirubin dropped to ≤3 times of the upper limit of normal value after PTCD had longer OS and PFS than patients >3 times.

[1]
Chidambaranathan-Reghupaty, S.; Fisher, P.B.; Sarkar, D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv. Cancer Res., 2021, 149, 1-61.
[http://dx.doi.org/10.1016/bs.acr.2020.10.001] [PMID: 33579421]
[2]
Kulik, L.; El-Serag, H.B. Epidemiology and management of hepatocellular carcinoma. Gastroenterology, 2019, 156(2), 477-491.e1.
[http://dx.doi.org/10.1053/j.gastro.2018.08.065] [PMID: 30367835]
[3]
Yang, J.D.; Hainaut, P.; Gores, G.J.; Amadou, A.; Plymoth, A.; Roberts, L.R. A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nat. Rev. Gastroenterol. Hepatol., 2019, 16(10), 589-604.
[http://dx.doi.org/10.1038/s41575-019-0186-y] [PMID: 31439937]
[4]
Dimitroulis, D.; Damaskos, C.; Valsami, S.; Davakis, S.; Garmpis, N.; Spartalis, E.; Athanasiou, A.; Moris, D.; Sakellariou, S.; Kykalos, S.; Tsourouflis, G.; Garmpi, A.; Delladetsima, I.; Kontzoglou, K.; Kouraklis, G. From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. World J. Gastroenterol., 2017, 23(29), 5282-5294.
[http://dx.doi.org/10.3748/wjg.v23.i29.5282] [PMID: 28839428]
[5]
Woo, H.Y.; Han, S.Y.; Heo, J.; Kim, D.U.; Baek, D.H.; Yoo, S.Y.; Kim, C.W.; Kim, S.; Song, G.A.; Cho, M.; Kang, D.H. Role of endoscopic biliary drainage in advanced hepatocellular carcinoma with jaundice. PLoS One, 2017, 12(11), e0187469.
[http://dx.doi.org/10.1371/journal.pone.0187469] [PMID: 29095941]
[6]
Minami, Y.; Kudo, M. Hepatocellular carcinoma with obstructive jaundice: endoscopic and percutaneous biliary drainage. Dig. Dis., 2012, 30(6), 592-597.
[http://dx.doi.org/10.1159/000343087] [PMID: 23258100]
[7]
Qin, L.X.; Tang, Z.Y. Hepatocellular carcinoma with obstructive jaundice: Diagnosis, treatment and prognosis. World J. Gastroenterol., 2003, 9(3), 385-391.
[http://dx.doi.org/10.3748/wjg.v9.i3.385] [PMID: 12632482]
[8]
Suh, Y.G.; Kim, D.Y.; Han, K.H.; Seong, J. Effective biliary drainage and proper treatment improve outcomes of hepatocellular carcinoma with obstructive jaundice. Gut Liver, 2014, 8(5), 526-535.
[http://dx.doi.org/10.5009/gnl13370] [PMID: 25071072]
[9]
Park, S.; Park, J.Y.; Chung, M.J.; Chung, J.B.; Park, S.W.; Han, K.H.; Song, S.Y.; Bang, S. The efficacy of endoscopic palliation of obstructive jaundice in hepatocellular carcinoma. Yonsei Med. J., 2014, 55(5), 1267-1272.
[http://dx.doi.org/10.3349/ymj.2014.55.5.1267] [PMID: 25048484]
[10]
Tanaka, T.; Kuzuya, T.; Ishigami, M.; Ito, T.; Ishizu, Y.; Honda, T.; Ishikawa, T.; Fujishiro, M. Efficacy and safety of sorafenib in unresectable hepatocellular carcinoma with bile duct invasion. Oncology, 2020, 98(9), 621-629.
[http://dx.doi.org/10.1159/000507051] [PMID: 32434180]
[11]
Lai, E.C.H.; Yee Lau, W. Hepatocellular carcinoma presenting with obstructive jaundice. ANZ J. Surg., 2006, 76(7), 631-636.
[http://dx.doi.org/10.1111/j.1445-2197.2006.03794.x] [PMID: 16813631]
[12]
Galle, P.R.; Forner, A.; Llovet, J.M.; Mazzaferro, V.; Piscaglia, F.; Raoul, J-L.; Schirmacher, P.; Vilgrain, V. European association for the study of the liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma. J. Hepatol., 2018, 69(1), 182-236.
[http://dx.doi.org/10.1016/j.jhep.2018.03.019] [PMID: 29628281]
[13]
Sugiyama, G.; Okabe, Y.; Ishida, Y.; Saitou, F.; Kawahara, R.; Ishikawa, H.; Horiuchi, H.; Kinoshita, H.; Tsuruta, O.; Sata, M. Evaluation of endoscopic biliary stenting for obstructive jaundice caused by hepatocellular carcinoma. World J. Gastroenterol., 2014, 20(22), 6968-6973.
[http://dx.doi.org/10.3748/wjg.v20.i22.6968] [PMID: 24944490]
[14]
An, J.; Lee, K.S.; Kim, K.M.; Park, D.H.; Lee, S.S.; Lee, D.; Shim, J.H.; Lim, Y.S.; Lee, H.C.; Chung, Y.H.; Lee, Y.S. Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion. Clin. Mol. Hepatol., 2017, 23(2), 160-169.
[http://dx.doi.org/10.3350/cmh.2016.0088] [PMID: 28506055]
[15]
Reig, M.; Forner, A.; Rimola, J.; Ferrer-Fàbrega, J.; Burrel, M.; Garcia-Criado, Á.; Kelley, R.K.; Galle, P.R.; Mazzaferro, V.; Salem, R.; Sangro, B.; Singal, A.G.; Vogel, A.; Fuster, J.; Ayuso, C.; Bruix, J. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J. Hepatol., 2022, 76(3), 681-693.
[http://dx.doi.org/10.1016/j.jhep.2021.11.018] [PMID: 34801630]
[16]
Na, S.K.; Yim, S.Y.; Suh, S.J.; Jung, Y.K.; Kim, J.H.; Seo, Y.S.; Yim, H.J.; Yeon, J.E.; Byun, K.S.; Um, S.H. ALBI versus Child-Pugh grading systems for liver function in patients with hepatocellular carcinoma. J. Surg. Oncol., 2018, 117(5), 912-921.
[http://dx.doi.org/10.1002/jso.24992] [PMID: 29448306]
[17]
Han, K.; Kim, J.H. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J. Gastroenterol., 2015, 21(36), 10327-10335.
[http://dx.doi.org/10.3748/wjg.v21.i36.10327] [PMID: 26420959]
[18]
Goldstein, H.M.; Wallace, S.; Anderson, J.H.; Bree, R.L.; Gianturco, C. Transcatheter occlusion of abdominal tumors. Radiology, 1976, 120(3), 539-545.
[http://dx.doi.org/10.1148/120.3.539] [PMID: 948584]
[19]
Petruzzi, P.; Crocetti, L.; Lencioni, R. Chemoembolization of hepatocellular carcinoma. Semin. Intervent. Radiol.,, 2013, 30(1), 003-011.
[http://dx.doi.org/10.1055/s-0033-1333648] [PMID: 24436512]
[20]
Sieghart, W.; Hucke, F.; Peck-Radosavljevic, M. Transarterial chemoembolization: Modalities, indication, and patient selection. J. Hepatol., 2015, 62(5), 1187-1195.
[http://dx.doi.org/10.1016/j.jhep.2015.02.010] [PMID: 25681552]
[21]
Li, S.; He, X.; Dang, L.; Xu, F.; Fang, J.; Li, F.; Wang, W. Efficacy of 125I versus Non-125I combined with transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma with obstructive jaundice. Dig. Dis. Sci., 2018, 63(2), 321-328.
[http://dx.doi.org/10.1007/s10620-017-4899-x] [PMID: 29305738]
[22]
Young, S.; Sanghvi, T.; Lake, J.J.; Rubin, N.; Golzarian, J. Predicting post-transarterial chemoembolization outcomes: A comparison of direct and total bilirubin serums levels. Diagn. Interv. Imaging, 2020, 101(6), 355-364.
[http://dx.doi.org/10.1016/j.diii.2019.12.006] [PMID: 31948887]
[23]
Thorat, A.; Lee, C.F.; Wu, T.H.; Chan, K.M.; Chou, H.S.; Lee, W.C. Safety of transarterial chemoembolization as bridging therapy in HCC patients with hyperbilirubinemia on the waiting list for liver transplantation: A centre experience. Hepatogastroenterology, 2013, 60(128), 2076-2079.
[PMID: 24719950]
[24]
Chandrashekhara, S.H.; Gamanagatti, S.; Singh, A.; Bhatnagar, S. Current status of percutaneous transhepatic biliary drainage in palliation of malignant obstructive jaundice: A review. Indian J. Palliat. Care, 2016, 22(4), 378-387.
[http://dx.doi.org/10.4103/0973-1075.191746] [PMID: 27803558]
[25]
Sun, J.J.; Wang, K.; Zhang, C.Z.; Guo, W.X.; Shi, J.; Cong, W.M.; Wu, M.C.; Lau, W.Y.; Cheng, S.Q. Postoperative adjuvant transcatheter arterial chemoembolization after R0 hepatectomy improves outcomes of patients who have hepatocellular carcinoma with microvascular invasion. Ann. Surg. Oncol., 2016, 23(4), 1344-1351.
[http://dx.doi.org/10.1245/s10434-015-5008-z] [PMID: 26714945]
[26]
Llovet, J.M.; Lencioni, R. mRECIST for HCC: Performance and novel refinements. J. Hepatol., 2020, 72(2), 288-306.
[http://dx.doi.org/10.1016/j.jhep.2019.09.026] [PMID: 31954493]
[27]
Tian, T.; Guo, J.; Hu, J.L.; Hu, Y.; Guo, P.; Yu, X.Y. Advanced hepatocellular carcinoma and palliative care: a scoping review. BMJ Support. Palliat. Care, 2022, 14(2), 163-170.
[http://dx.doi.org/10.1136/spcare-2022-003798] [PMID: 36396345]
[28]
Rammohan, A.; Sathyanesan, J.; Rajendran, K.; Pitchaimuthu, A.; Perumal, S.K.; Balaraman, K.; Ramasamy, R.; Palaniappan, R.; Govindan, M. Bile duct thrombi in hepatocellular carcinoma: Is aggressive surgery worthwhile? HPB (Oxford), 2015, 17(6), 508-513.
[http://dx.doi.org/10.1111/hpb.12383] [PMID: 25639610]
[29]
Fargo, M.V.; Grogan, S.P.; Saguil, A. Evaluation of jaundice in adults. Am. Fam. Physician, 2017, 95(3), 164-168.
[PMID: 28145671]
[30]
Bhattarai, S.; Graham, R.P.; Sigel, C.S.; Shi, J.; Gonzalez, R.S.; Xue, Y.; Krasinskas, A.M. HooKim, K.; Adsay, V.; Reid, M.D. Bile duct involvement by hepatocellular carcinoma: A rare occurrence and poor prognostic indicator in bile duct brushing samples. Cancer Cytopathol., 2019, 127(11), 691-699.
[http://dx.doi.org/10.1002/cncy.22185] [PMID: 31518056]
[31]
Jeon, SH.; Park, KS.; Kim, YH.; Shin, YS.; Kang, MK.; Jang, BK.; Chung, WJ.; Cho, KB.; Hwang, JS. Incidence and risk factors of acute hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma. Korean J. Gastroenterol., 2007, 50(3), 176-182.
[http://dx.doi.org/10.1111/ecc.12858] [PMID: 17885283]
[32]
Tong, D.; Wu, L.; Chen, X.; Li, Y. Post-operative care of interventional therapy for 40 liver cancer patients with obstructive jaundice. Eur. J. Cancer Care (Engl.), 2018, 27(4), e12858.
[http://dx.doi.org/10.1111/ecc.12858] [PMID: 29767833]
[33]
Zhang, C.; Yang, Y.; Wu, P.; Ma, Y.; Zhang, H.; Lin, M.; Shi, L.; Li, J.; Zhao, M. Prevention and treatment of complications for full-covered self-expanding removable metal stents in malignant obstructive jaundice. Zhonghua Yi Xue Za Zhi, 2015, 95(6), 416-419.
[PMID: 25916776]
[34]
Sacco, R.; Tapete, G.; Simonetti, N.; Sellitri, R.; Natali, V.; Melissari, S.; Cabibbo, G.; Biscaglia, L.; Bresci, G.; Giacomelli, L. Transarterial chemoembolization for the treatment of hepatocellular carcinoma: A review. J. Hepatocell. Carcinoma, 2017, 4, 105-110.
[http://dx.doi.org/10.2147/JHC.S103661] [PMID: 28795053]
[35]
Khalid, M.A.; Achakzai, I.K.; Hanif, F.M.; Ahmed, S.; Majid, Z.; Luck, N.H. To determine the prognostic value of the albumin-bilirubin grade (ALBI) in patients underwent transarterial chemoembolization for unresectable hepatocellular carcinoma. Gastroenterol. Hepatol. Bed Bench, 2019, 12(2), 110-115.
[PMID: 31191834]
[36]
Li, L.; Mo, F.; Hui, E.P.; Chan, S.L.; Koh, J.; Tang, N.L.S.; Yu, S.C.H.; Yeo, W. The association of liver function and quality of life of patients with liver cancer. BMC Gastroenterol., 2019, 19(1), 66.
[http://dx.doi.org/10.1186/s12876-019-0984-2] [PMID: 31046687]
[37]
Tellapuri, S.; Sutphin, P.D.; Beg, M.S.; Singal, A.G.; Kalva, S.P. Staging systems of hepatocellular carcinoma: A review. Indian J. Gastroenterol., 2018, 37(6), 481-491.
[http://dx.doi.org/10.1007/s12664-018-0915-0] [PMID: 30593649]
[38]
Bruix, J.; Reig, M.; Sherman, M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology, 2016, 150(4), 835-853.
[http://dx.doi.org/10.1053/j.gastro.2015.12.041] [PMID: 26795574]
[39]
Díaz-González, Á.; Reig, M.; Bruix, J. Treatment of hepatocellular carcinoma. Dig. Dis., 2016, 34(5), 597-602.
[http://dx.doi.org/10.1159/000445275] [PMID: 27332893]
[40]
Liang, X.; Liangliang, X.; Peng, W.; Tao, Y.; Jinfu, Z.; Ming, Z.; Mingqing, X. Combined prognostic nutritional index and albumin-bilirubin grade to predict the postoperative prognosis of HBV-associated hepatocellular carcinoma patients. Sci. Rep., 2021, 11(1), 14624.
[http://dx.doi.org/10.1038/s41598-021-94035-5] [PMID: 34272447]
[41]
Brown, D.B.; Fundakowski, C.E.; Lisker-Melman, M.; Crippin, J.S.; Pilgram, T.K.; Chapman, W.; Darcy, M.D. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J. Vasc. Interv. Radiol., 2004, 15(11), 1209-1218.
[http://dx.doi.org/10.1097/01.RVI.0000128123.04554.C1] [PMID: 15525739]
[42]
Cabibbo, G.; Genco, C.; Di Marco, V.; Barbara, M.; Enea, M.; Parisi, P.; Brancatelli, G.; Romano, P.; Craxì, A.; Cammà, C. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. Aliment. Pharmacol. Ther., 2011, 34(2), 196-204.
[http://dx.doi.org/10.1111/j.1365-2036.2011.04694.x] [PMID: 21564144]
[43]
Choi, J.; Ryu, J.K.; Lee, S.H.; Ahn, D.W.; Hwang, J.H.; Kim, Y.T.; Yoon, Y.B.; Han, J.K. Biliary drainage for obstructive jaundice caused by unresectable hepatocellular carcinoma: the endoscopic versus percutaneous approach. Hepatobiliary Pancreat. Dis. Int., 2012, 11(6), 636-642.
[http://dx.doi.org/10.1016/S1499-3872(12)60237-9] [PMID: 23232636]
[44]
Cho, H.C.; Lee, J.K.; Lee, K.H.; Lee, K.T.; Paik, S.; Choo, S.W.; Do, Y.S.; Choo, I.W. Are endoscopic or percutaneous biliary drainage effective forobstructive jaundice caused by hepatocellular carcinoma? Eur. J. Gastroenterol. Hepatol., 2011, 23(3), 224-231.
[http://dx.doi.org/10.1097/MEG.0b013e3283436ff6] [PMID: 21228705]
[45]
Bao, G.; Liu, H.; Ma, Y.; Li, N.; Lv, F.; Dong, X.; Chen, X. The clinical efficacy and safety of different biliary drainages in malignant obstructive jaundice treatment. Am. J. Transl. Res., 2021, 13(6), 7400-7405.
[PMID: 34306512]
[46]
Alatise, O.; Owojuyigbe, A.; Omisore, A.; Ndububa, D.; Aburime, E.; Dua, K.; Asombang, A. Endoscopic management and clinical outcomes of obstructive jaundice. Niger. Postgrad. Med. J., 2020, 27(4), 302-310.
[http://dx.doi.org/10.4103/npmj.npmj_242_20] [PMID: 33154282]
[47]
Zerem, E.; Imširović, B.; Kunosić, S.; Zerem, D.; Zerem, O. Percutaneous biliary drainage for obstructive jaundice in patients with inoperable, malignant biliary obstruction. Clin. Exp. Hepatol., 2022, 8(1), 70-77.
[http://dx.doi.org/10.5114/ceh.2022.114190] [PMID: 35415254]
[48]
Duan, F.; Cui, L.; Bai, Y.; Li, X.; Yan, J.; Liu, X. Comparison of efficacy and complications of endoscopic and percutaneous biliary drainage in malignant obstructive jaundice: A systematic review and meta-analysis. Cancer Imaging, 2017, 17(1), 27.
[http://dx.doi.org/10.1186/s40644-017-0129-1] [PMID: 29037223]
[49]
Rizzo, A.; Ricci, A.D.; Frega, G.; Palloni, A.; De Lorenzo, S.; Abbati, F.; Mollica, V.; Tavolari, S.; Di Marco, M.; Brandi, G. How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis. In Vivo, 2020, 34(4), 1701-1714.
[http://dx.doi.org/10.21873/invivo.11964] [PMID: 32606139]
[50]
Liu, Y.M.; Ren, Y.Q.; Song, S.L.; Zheng, C.S. Pyogenic liver abscess in non-liver cancer patients and liver cancer patients treated with TACE: Etiological characteristics, treatment, and outcome analysis. Kaohsiung J. Med. Sci., 2022.
[http://dx.doi.org/10.1002/kjm2.12613] [PMID: 36354204]
[51]
Lv, W.F.; Lu, D.; He, Y.S.; Xiao, J.K.; Zhou, C.Z.; Cheng, D.L. Liver abscess formation following transarterial chemoembolization. Medicine (Baltimore), 2016, 95(17), e3503.
[http://dx.doi.org/10.1097/MD.0000000000003503] [PMID: 27124055]
[52]
Scartozzi, M.; Baroni, G.S.; Faloppi, L.; Paolo, M.D.P.; Pierantoni, C.; Candelari, R.; Berardi, R.; Antognoli, S.; Mincarelli, C.; Risaliti, A.; Marmorale, C.; Antico, E.; Benedetti, A.; Cascinu, S. Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: Efficacy and safety results from a large mono-institutional analysis. J. Exp. Clin. Cancer Res., 2010, 29(1), 164.
[http://dx.doi.org/10.1186/1756-9966-29-164] [PMID: 21159184]
[53]
Mohammadifard, M.; Ghanaati, H.; Mohammadifard, M. A review of applying transarterial chemoembolization (TACE) method for management of hepatocellular carcinoma. J. Family Med. Prim. Care, 2021, 10(10), 3553-3560.
[http://dx.doi.org/10.4103/jfmpc.jfmpc_2347_20] [PMID: 34934646]
[54]
Dai, Q.S.; Gu, H.L.; Ye, S.; Zhang, Y.J.; Lin, X.J.; Lau, W.Y.; Peng, Z.W.; Chen, M.S. Transarterial chemoembolization vs. conservative treatment for unresectable infiltrating hepatocellular carcinoma: A retrospective comparative study. Mol. Clin. Oncol., 2014, 2(6), 1047-1054.
[http://dx.doi.org/10.3892/mco.2014.391] [PMID: 25279196]
[55]
Kong, J.Y.; Li, S.M.; Fan, H.Y.; Zhang, L.; Zhao, H.J.; Li, S.M. Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma. Medicine (Baltimore), 2018, 97(33), e11872.
[http://dx.doi.org/10.1097/MD.0000000000011872] [PMID: 30113483]
[56]
Lu, J.; Zhao, M.; Arai, Y.; Zhong, B.Y.; Zhu, H.D.; Qi, X.L.; Baere, T.; Pua, U.; Yoon, H.K.; Madoff, D.C.; Teng, G.J. Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: Consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO). Hepatobiliary Surg. Nutr., 2021, 10(5), 661-671.
[http://dx.doi.org/10.21037/hbsn-21-260] [PMID: 34760969]
[57]
Lee, J.W.; Han, J.K.; Kim, T.K.; Choi, B.I.; Park, S.H.; Ko, Y.H.; Yoon, C.J.; Yeon, K.M. Obstructive jaundice in hepatocellular carcinoma: response after percutaneous transhepatic biliary drainage and prognostic factors. Cardiovasc. Intervent. Radiol., 2002, 25(3), 176-179.
[http://dx.doi.org/10.1007/s00270-001-0100-0] [PMID: 12058212]
[58]
Park, K.H.; Kim, J.H.; Choe, W.H.; Kwon, S.Y.; Yoo, B.C.; Hwang, J.H.; Park, S.W.; Kim, Y.J.; Park, H.S.; Yu, M.H.; Jeon, H.J. Risk factors for liver function deterioration after transarterial chemoembolization refractoriness in child-pugh class a hepatocellular carcinoma patients. Korean J. Gastroenterol., 2020, 75(3), 147-156.
[http://dx.doi.org/10.4166/kjg.2020.75.3.147] [PMID: 32209803]
[59]
Chen, Y.; Yan, Z.P.; Wang, J.H.; Wang, X.L.; Cheng, J.M.; Gong, G.Q.; Liu, Q.X.; Qian, S.; Liu, R.; Luo, J.J. Epirubicin in the treatment of malignant obstructive jaundice. Zhonghua Zhong Liu Za Zhi, 2006, 28(5), 397-399.
[PMID: 17045011]
[60]
Li, M.Q.; Zhang, J.X.; Lu, C.H.; Pan, H.; Ru, F.M.; Cao, C.W.; Xu, J.C.; Xu, J.H. Long-term outcome of interventional therapy for malignant biliary obstruction: A retrospective analysis of 109 cases. Zhonghua Yi Xue Za Zhi, 2008, 88(39), 2743-2747.
[PMID: 19080446]
[61]
Tian, S.; Quan, H.; Xie, C.; Guo, H.; Lü, F.; Xu, Y.; Li, J.; Lou, L. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci., 2011, 102(7), 1374-1380.
[http://dx.doi.org/10.1111/j.1349-7006.2011.01939.x] [PMID: 21443688]
[62]
Yu, W.C.; Zhang, K.Z.; Chen, S.G.; Liu, W.F. Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma. Medicine (Baltimore), 2018, 97(3), e9704.
[http://dx.doi.org/10.1097/MD.0000000000009704] [PMID: 29505026]
[63]
Wang, Y.; Gou, Q.; Xu, R.; Chen, X.; Zhou, Z. Efficacy and safety of sorafenib versus apatinib in the treatment of intermediate and advanced hepatocellular carcinoma: A comparative retrospective study. OncoTargets Ther., 2018, 11, 3407-3413.
[http://dx.doi.org/10.2147/OTT.S161023] [PMID: 29928132]
[64]
Zhen, L.; Jiali, C.; Yong, F.; Han, X.; Hongming, P.; Weidong, H. The efficacy and safety of apatinib treatment for patients with unresectable or relapsed liver cancer: A retrospective study. J. Cancer, 2018, 9(16), 2773-2777.
[http://dx.doi.org/10.7150/jca.26376] [PMID: 30123344]
[65]
Hu, Y.; Lin, H.; Hao, M.; Zhou, Y.; Chen, Q.; Chen, Z. Efficacy and safety of apatinib in treatment of unresectable intrahepatic cholangiocarcinoma: An observational study. Cancer Manag. Res., 2020, 12, 5345-5351.
[http://dx.doi.org/10.2147/CMAR.S254955] [PMID: 32753952]
[66]
Shimohira, M.; Ogino, H.; Kawai, T.; Sakurai, K.; Nakagawa, M.; Shibamoto, Y. Clinical usefulness of the triaxial system in super-selective transcatheter arterial chemoembolization for hepatocellular carcinoma. Acta Radiol., 2012, 53(8), 857-861.
[http://dx.doi.org/10.1258/ar.2012.120044] [PMID: 22850577]
[67]
Choi, J.W.; Chung, J.W.; Cho, Y.K.; Kim, Y.J.; Yoon, J.H.; Kim, H.C.; Jae, H.J. Transarterial chemoembolization for hepatocellular carcinomas with central bile duct invasion: Safety, prognosis, and predictive factors. Cardiovasc. Intervent. Radiol., 2015, 38(4), 937-945.
[http://dx.doi.org/10.1007/s00270-014-1032-9] [PMID: 25465065]
[68]
Bannangkoon, K.; Hongsakul, K.; Tubtawee, T.; Mc Neil, E.; Sriplung, H.; Chongsuwiwatvong, V. Rate and predictive factors for sustained complete response after selective transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma. Asian Pac. J. Cancer Prev., 2018, 19(12), 3545-3550.
[http://dx.doi.org/10.31557/APJCP.2018.19.12.3545] [PMID: 30583681]
[69]
Sacco, R.; Bertini, M.; Petruzzi, P.; Bertoni, M.; Bargellini, I.; Bresci, G.; Federici, G.; Gambardella, L.; Metrangolo, S.; Parisi, G.; Romano, A.; Scaramuzzino, A.; Tumino, E.; Silvestri, A.; Altomare, E.; Vignali, C.; Capria, A. Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: A cohort study. World J. Gastroenterol., 2009, 15(15), 1843-1848.
[http://dx.doi.org/10.3748/wjg.15.1843] [PMID: 19370781]
[70]
Yan, L.; Ren, Y.; Qian, K.; Kan, X.; Zhang, H.; Chen, L.; Liang, B.; Zheng, C. Superselective transarterial chemoembolization for unresectable or “ablation unsuitable” hepatocellular carcinoma in the caudate lobe: A real world, single-center retrospective study. Front. Oncol., 2021, 11, 678847.
[http://dx.doi.org/10.3389/fonc.2021.678847] [PMID: 34778023]
[71]
Inui, K.; Takahashi, Y.; Komeichi, H.; Katsuta, Y.; Shimizu, S.; Mizuno, K. Successful transcatheter chemoembolization for acute jaundice in a patient with advanced hepatocellular carcinoma and portal vein tumor thrombosis: A case report. J. Nippon Med. Sch., 2009, 76(4), 217-220.
[http://dx.doi.org/10.1272/jnms.76.217] [PMID: 19755798]
[72]
Choi, J.; Ryu, J.K.; Lee, S.H.; Hwang, J.H.; Ahn, D.W.; Kim, Y.T.; Yoon, Y.B.; Yoon, C.J.; Kang, S.G.; Chung, J.W. Palliative treatment of unresectable hepatocellular carcinoma with obstructive jaundice using biliary drainage with subsequent transarterial chemoembolization. J. Palliat. Med., 2013, 16(9), 1026-1033.
[http://dx.doi.org/10.1089/jpm.2013.0067] [PMID: 23888306]
[73]
Olivo, M.; Valenza, F.; Buccellato, A.; Scala, L.; Virdone, R.; Sciarrino, E.; Di Piazza, S.; Marrone, C.; Orlando, A.; Fusco, G.; Madonia, S.; Cottone, M. Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: Survival rate and prognostic factors. Dig. Liver Dis., 2010, 42(7), 515-519.
[http://dx.doi.org/10.1016/j.dld.2009.09.012] [PMID: 19914153]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy